Rodman & Renshaw sets $8 target for Rein Therapeutics stock
Rein Therapeutics (NASDAQ:RNTX) received a Buy rating from Rodman & Renshaw, with a newly established price target of $8.00. The firm began its coverage of the biotech company, highlighting its focus ...
BlackDoctor2h
When Cystic Fibrosis Hits the Lungs, HIT BACK
When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...
Managed Healthcare Executive4h
Key Unmet Needs in PPF Management
Panelists discuss the key gaps and unmet needs in current management strategies for progressive pulmonary fibrosis (PPF) and ...